drugset / Trial / NCT00948922
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Phase 2
Completed
124 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
Timeline
- Start
- 2009-06-18
- Primary completion
- 2017-04-20
- Completion
- 2019-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 100 mg/m2 | Intravenous |